PT - JOURNAL ARTICLE AU - Schweizer, Lisa AU - Schaller, Tina AU - Zwiebel, Maximilian AU - Karayel, Özge AU - Müller-Reif, Johannes B. AU - Zeng, Wen-Feng AU - Dintner, Sebastian AU - Hirschbühl, Klaus AU - Märkl, Bruno AU - Claus, Rainer AU - Mann, Matthias TI - Quantitative multi-organ proteomics of fatal COVID-19 uncovers tissue-specific effects beyond inflammation AID - 10.1101/2022.12.21.22283785 DP - 2022 Jan 01 TA - medRxiv PG - 2022.12.21.22283785 4099 - http://medrxiv.org/content/early/2022/12/22/2022.12.21.22283785.short 4100 - http://medrxiv.org/content/early/2022/12/22/2022.12.21.22283785.full AB - SARS-CoV-2 directly damages lung tissue via its infection and replication process and indirectly due to systemic effects of the host immune system. There are few systems-wide, untargeted studies of these effects on the different tissues of the human body and nearly all of them base their conclusions on the transcriptome. Here we developed a parallelized mass spectrometry (MS)-based proteomics workflow allowing the rapid, quantitative analysis of hundreds of virus-infected and FFPE preserved tissues. The first layer of response in all tissues was dominated by circulating inflammatory molecules. To discriminated between these systemic and true tissue-specific effects, we developed an analysis pipeline revealing that proteome alterations reflect extensive tissue damage, mostly similar to non-COVID diffuse alveolar damage. The next most affected organs were kidney and liver, while the lymph-vessel system was also strongly affected. Finally, secondary inflammatory effects of the brain correlated with receptor rearrangements and the degradation of neuronal myelin. Our results establish MS-based tissue proteomics as a promising strategy to inform organ-specific therapeutic interventions following COVID-19 infections.Competing Interest StatementMatthias Mann is an indirect investor of the Evosep company. All other authors declare no competing interests.Funding StatementThe study was funded by the Max Planck Society for the Advancement of Science, the German Registry of COVID-19 Autopsies (www.DeRegCOVID.ukaachen.de) and the Bavarian Ministry of Science and the Arts.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board (IRB) of the Universitaetsklinikum Augsburg (UKA, University Hospital Augsburg) (BKF No. 2020-18) gave ethical approval for this work. The ethics committee of the University of Munich (Project number 20-426, COVID-19 registry of the University Hospital Augsburg) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be publicly available upon publication in a journal.